Innoviva Inc - Asset Resilience Ratio
Innoviva Inc (INVA) has an Asset Resilience Ratio of 0.51% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Innoviva Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Innoviva Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Innoviva Inc.
Liquid Assets Composition Over Time
This chart breaks down Innoviva Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Innoviva Inc (INVA) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $8.67 Million | 0.51% |
| Total Liquid Assets | $8.67 Million | 0.51% |
Asset Resilience Insights
- Limited Liquidity: Innoviva Inc maintains only 0.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Innoviva Inc Industry Peers by Asset Resilience Ratio
Compare Innoviva Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Innoviva Inc (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Innoviva Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.96% | $15.73 Million | $1.64 Billion | -7.30pp |
| 2024-12-31 | 8.26% | $107.53 Million | $1.30 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $1.24 Billion | -- |
| 2022-12-31 | 32.73% | $403.01 Million | $1.23 Billion | -19.50pp |
| 2021-12-31 | 52.23% | $483.85 Million | $926.39 Million | +8.38pp |
| 2020-12-31 | 43.84% | $438.26 Million | $999.57 Million | +33.81pp |
| 2019-12-31 | 10.04% | $72.75 Million | $724.83 Million | +0.46pp |
| 2018-12-31 | 9.58% | $52.49 Million | $548.19 Million | -5.60pp |
| 2017-12-31 | 15.17% | $55.74 Million | $367.34 Million | +6.62pp |
| 2016-12-31 | 8.55% | $32.42 Million | $379.00 Million | +1.93pp |
| 2015-12-31 | 6.63% | $28.10 Million | $424.07 Million | -20.92pp |
| 2014-12-31 | 27.55% | $143.70 Million | $521.65 Million | -19.66pp |
| 2013-12-31 | 47.21% | $321.62 Million | $681.25 Million | +5.53pp |
| 2012-12-31 | 41.68% | $153.64 Million | $368.58 Million | -34.11pp |
| 2011-12-31 | 75.79% | $196.14 Million | $258.78 Million | +31.62pp |
| 2010-12-31 | 44.17% | $146.30 Million | $331.20 Million | -15.28pp |
| 2009-12-31 | 59.45% | $107.85 Million | $181.39 Million | +13.58pp |
| 2008-12-31 | 45.87% | $108.33 Million | $236.16 Million | +20.94pp |
| 2007-12-31 | 24.93% | $40.38 Million | $161.98 Million | -24.11pp |
| 2006-12-31 | 49.04% | $128.69 Million | $262.42 Million | -0.84pp |
| 2005-12-31 | 49.88% | $112.14 Million | $224.84 Million | -4.57pp |
| 2004-12-31 | 54.45% | $155.73 Million | $286.02 Million | +11.88pp |
| 2003-12-31 | 42.57% | $53.40 Million | $125.45 Million | +21.94pp |
| 2002-12-31 | 20.63% | $39.75 Million | $192.72 Million | -- |
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more